Asked by: Wendy Morton (Conservative - Aldridge-Brownhills)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, with reference to HCWS1248, what estimate has been made of the annual cost to the NHS of expanding access to abiraterone; what savings have been achieved through the availability of generic versions of the drug; and how value for money will be assessed over the course of the commissioning policy.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
Approximately 2,000 men diagnosed in the last three months with non‑metastatic prostate cancer will now be able to receive abiraterone where it is of clinical benefit, alongside prednisolone. An additional 7,000 men are expected to be diagnosed with prostate cancer each year and will be eligible for the drug. The clinical treatment criteria are available via the Cancer Drugs Fund list at the following link:
https://www.england.nhs.uk/publication/national-cancer-drugs-fund-list/
These national clinical treatment criteria ensure equity of access for patients across England.
NHS England sets national service standards for those elements of cancer care designated as specialised services. Integrated care boards, supported by Cancer Alliances, are expected to plan and organise access to prostate cancer treatment in line with national standards. The integration of specialised and nonspecialised commissioning allows them to join up care and target resources where they can have the greatest impact on outcomes.
The National Prostate Cancer Audit (NPCA) assesses the process of care and its outcomes in men diagnosed with prostate cancer in England and Wales. Further information about the NPCA can be found via the National Disease Registration Service at the following link:
https://digital.nhs.uk/ndrs/our-work/ncras-partnerships/national-prostate-cancer-audit-npca
Information regarding the annual cost of expanding access to abiraterone is commercially sensitive. The availability of generic abiraterone means the National Health Service in England can procure the treatment at a lower cost than Zytiga under patent. NHS England has been able to give the green light to the rollout of generic abiraterone for thousands more eligible patients thanks to the health service buying and delivering treatments at better value, following the clinical advice to roll the treatment out last year.
Asked by: Wendy Morton (Conservative - Aldridge-Brownhills)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, with reference to HCWS1248, what assessment has been made of existing regional variation in access to prostate cancer treatments and what steps are being taken to prevent disparities in uptake between different NHS trusts and integrated care boards.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
Approximately 2,000 men diagnosed in the last three months with non‑metastatic prostate cancer will now be able to receive abiraterone where it is of clinical benefit, alongside prednisolone. An additional 7,000 men are expected to be diagnosed with prostate cancer each year and will be eligible for the drug. The clinical treatment criteria are available via the Cancer Drugs Fund list at the following link:
https://www.england.nhs.uk/publication/national-cancer-drugs-fund-list/
These national clinical treatment criteria ensure equity of access for patients across England.
NHS England sets national service standards for those elements of cancer care designated as specialised services. Integrated care boards, supported by Cancer Alliances, are expected to plan and organise access to prostate cancer treatment in line with national standards. The integration of specialised and nonspecialised commissioning allows them to join up care and target resources where they can have the greatest impact on outcomes.
The National Prostate Cancer Audit (NPCA) assesses the process of care and its outcomes in men diagnosed with prostate cancer in England and Wales. Further information about the NPCA can be found via the National Disease Registration Service at the following link:
https://digital.nhs.uk/ndrs/our-work/ncras-partnerships/national-prostate-cancer-audit-npca
Information regarding the annual cost of expanding access to abiraterone is commercially sensitive. The availability of generic abiraterone means the National Health Service in England can procure the treatment at a lower cost than Zytiga under patent. NHS England has been able to give the green light to the rollout of generic abiraterone for thousands more eligible patients thanks to the health service buying and delivering treatments at better value, following the clinical advice to roll the treatment out last year.
Asked by: Wendy Morton (Conservative - Aldridge-Brownhills)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, with reference to HCWS1248, how many patients with non-metastatic prostate cancer are expected to be eligible for abiraterone in each of the next three financial years; what clinical criteria determine eligibility; and how NHS England will ensure consistent access across all integrated care boards.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
Approximately 2,000 men diagnosed in the last three months with non‑metastatic prostate cancer will now be able to receive abiraterone where it is of clinical benefit, alongside prednisolone. An additional 7,000 men are expected to be diagnosed with prostate cancer each year and will be eligible for the drug. The clinical treatment criteria are available via the Cancer Drugs Fund list at the following link:
https://www.england.nhs.uk/publication/national-cancer-drugs-fund-list/
These national clinical treatment criteria ensure equity of access for patients across England.
NHS England sets national service standards for those elements of cancer care designated as specialised services. Integrated care boards, supported by Cancer Alliances, are expected to plan and organise access to prostate cancer treatment in line with national standards. The integration of specialised and nonspecialised commissioning allows them to join up care and target resources where they can have the greatest impact on outcomes.
The National Prostate Cancer Audit (NPCA) assesses the process of care and its outcomes in men diagnosed with prostate cancer in England and Wales. Further information about the NPCA can be found via the National Disease Registration Service at the following link:
https://digital.nhs.uk/ndrs/our-work/ncras-partnerships/national-prostate-cancer-audit-npca
Information regarding the annual cost of expanding access to abiraterone is commercially sensitive. The availability of generic abiraterone means the National Health Service in England can procure the treatment at a lower cost than Zytiga under patent. NHS England has been able to give the green light to the rollout of generic abiraterone for thousands more eligible patients thanks to the health service buying and delivering treatments at better value, following the clinical advice to roll the treatment out last year.
Asked by: Wendy Morton (Conservative - Aldridge-Brownhills)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, with reference to HCWS1248, what arrangements are in place to monitor patient outcomes following the expanded use of abiraterone at earlier stages of prostate cancer; and whether those outcomes will be published on a national and regional basis.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
Approximately 2,000 men diagnosed in the last three months with non‑metastatic prostate cancer will now be able to receive abiraterone where it is of clinical benefit, alongside prednisolone. An additional 7,000 men are expected to be diagnosed with prostate cancer each year and will be eligible for the drug. The clinical treatment criteria are available via the Cancer Drugs Fund list at the following link:
https://www.england.nhs.uk/publication/national-cancer-drugs-fund-list/
These national clinical treatment criteria ensure equity of access for patients across England.
NHS England sets national service standards for those elements of cancer care designated as specialised services. Integrated care boards, supported by Cancer Alliances, are expected to plan and organise access to prostate cancer treatment in line with national standards. The integration of specialised and nonspecialised commissioning allows them to join up care and target resources where they can have the greatest impact on outcomes.
The National Prostate Cancer Audit (NPCA) assesses the process of care and its outcomes in men diagnosed with prostate cancer in England and Wales. Further information about the NPCA can be found via the National Disease Registration Service at the following link:
https://digital.nhs.uk/ndrs/our-work/ncras-partnerships/national-prostate-cancer-audit-npca
Information regarding the annual cost of expanding access to abiraterone is commercially sensitive. The availability of generic abiraterone means the National Health Service in England can procure the treatment at a lower cost than Zytiga under patent. NHS England has been able to give the green light to the rollout of generic abiraterone for thousands more eligible patients thanks to the health service buying and delivering treatments at better value, following the clinical advice to roll the treatment out last year.
Asked by: Wendy Morton (Conservative - Aldridge-Brownhills)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 25 November 2025 to Question 90706, how the Neighbourhood Health Service will improve access to care in rural areas and communities with poor digital connectivity or low digital confidence in the West Midlands; what safeguards are in place to ensure that neighbourhood health centres do not lead to the downgrading or closure of existing GP surgeries or community hospitals; what evaluation he has made of previous neighbourhood care pilots in the region; and what timetable he has set for expanding the programme beyond wave 1, including the inclusion of additional West Midlands areas.
Answered by Stephen Kinnock - Minister of State (Department of Health and Social Care)
The Neighbourhood Health Service will make it easier for people to access care closer to where they live, including in neighbourhood health centres. Delivery will be locally led, with systems determining how neighbourhood health is designed to meet local population need. This will factor in how services may need to look different across rural and urban areas.
The Neighbourhood Health Service will also move us towards a fully digitally enabled health service. We are striving for digital services to improve access, experiences, and outcomes for the widest range of people, based on their preferences, as any digital healthcare benefits will be limited if people remain digitally excluded.
Neighbourhood health provides the unifying framework that brings together what is already underway across primary care, community services, urgent care, prevention, digital, estates, and population health, and will build on existing assets and services rather than replacing them. We are intending to publish further guidance that will set-out how areas should work together to design neighbourhood health services around local needs and different population cohorts.
In September 2025, we launched the National Neighbourhood Health Implementation Programme (NNHIP) in 43 places across England, including in East Birmingham. Collection of metrics is currently being piloted across all NNHIP sites. Systems are also encouraged to participate in the monthly Community of Practice, that aims to share learning and strengthen collective delivery.
Work is underway to consider the future direction of the NNHIP, and we will share an update on this as soon as we can.
Asked by: Wendy Morton (Conservative - Aldridge-Brownhills)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 25 November 2025 to Question 90706, what funding has been allocated to each West Midlands area participating in wave 1 of the National Neighbourhood Health Implementation Programme; how much of that funding represents new investment rather than existing budgets; what assessment he has made of the programme’s impact on GP access, community nursing capacity and waiting times in Walsall, Coventry, Shropshire, East Birmingham, Solihull and Herefordshire; and what metrics will be used to evaluate success, including whether place-level data will be published.
Answered by Stephen Kinnock - Minister of State (Department of Health and Social Care)
National Neighbourhood Health Implementation Programme (NNHIP) sites have not been allocated additional funding. NNHIP sites have been provided with expert and peer support to facilitate learning and sharing solutions. This support helps sites tackle challenges, deliver improvements, adapt solutions to their own circumstances, and spread best practices across all sites.
Collection of outcome metrics is currently being piloted across NNHIP sites. A measurement guide has been co-produced with NNHIP sites. Data collection for this will begin in early 2026 which will take some time to embed and then analyse. In the interim, sites are producing case studies showcasing what has worked for their populations and the learning from these case studies are shared as part of the improvement programme with the 43 sites, as well as the national community of practice, open to all places. In addition, four deep-dive case studies are planned, providing an in-depth view of the conditions for success across four geographically and demographically different places across the country.
Asked by: Wendy Morton (Conservative - Aldridge-Brownhills)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 25 November 2025 to Question 90706, how neighbourhood health services in the West Midlands will be staffed in practice; what steps are being taken to address workforce shortages in general practice, community nursing and district nursing; what role Integrated Care Boards and elected local authorities will play in the design and oversight of neighbourhood health services; and how democratic accountability will be ensured.
Answered by Stephen Kinnock - Minister of State (Department of Health and Social Care)
The 10 Year Workforce Plan will ensure the National Health Service has the right people in the right places, with the right skills to care for patients, when they need it.
Neighbourhood health services will bring together integrated neighbourhood teams of professionals and partners closer to people’s home, including nurses, doctors, social care workers, pharmacists, health visitors, employment support, children’s services, and more, to work together to support people and places to improve their health and wellbeing.
Integrated care boards (ICBs) are responsible for commissioning, which includes planning, securing, and monitoring, general practice services within their health systems through delegated responsibility from NHS England. Both ICBs and local health systems will be responsible for designing neighbourhood health services and centres that reflect the needs of their local populations. This will be the case for determining neighbourhood health services and staffing in the West Midlands.
The 10-Year Health Plan committed to neighbourhood health plans that will be drawn up in partnership with ICBs, local authorities, and partners.
Asked by: Wendy Morton (Conservative - Aldridge-Brownhills)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential public health risks arising from the withdrawal of waste collection services in Birmingham following the decision by agency refuse workers to take industrial action from 1 December 2025.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The Director of Public Health for Birmingham continues to monitor the situation locally, including any public health risks from uncollected waste. The UK Health Security Agency, working closely with relevant partner organisations, would contribute to any risk assessment and provide health protection advice and support as requested.
Asked by: Wendy Morton (Conservative - Aldridge-Brownhills)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, with reference to the Written Statement entitled Mental Health Conditions, Autism and ADHD Prevalence and Support, published on 4 December 2025, HCWS1132, what criteria will be used to appoint members to the Advisory Working Group, how individuals with lived experience will be involved in the development and scrutiny of the Review’s findings, and what steps he plans to take to ensure that any recommendations accepted by the Government are implemented uniformly across Integrated Care Boards and local authorities, with transparent reporting and measurable outcomes.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The Chair and vice-chairs of the independent review into the prevalence of and support for mental health conditions, attention deficit hyperactivity disorder (ADHD), and autism will appoint an Advisory Working Group which involves a multidisciplinary group of leading academics, clinicians, epidemiological experts, charities, and people with lived experience to directly shape the recommendations and scrutinise the evidence. As the review is independent it is for the chairs to determine the process for engaging.
The Government has begun to address fundamental problems in National Health Service mental health services and will progress towards a new approach for mental health in 2026. As part of this we are radically enhancing transparency of mental health providers with consequences for poor performance. New league tables are driving improvement in the quality and safety of care, rewarding improvement and success. We are tackling unacceptable failures in care quality through stronger accountability and enhanced support.
Asked by: Wendy Morton (Conservative - Aldridge-Brownhills)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, with reference to the Written Statement entitled Mental Health Conditions, Autism and ADHD Prevalence and Support, published on 4 December 2025, HCWS1132, what assessment he has made of regional variation in diagnostic practice, referral thresholds and waiting times for autism and ADHD assessments; whether the Independent Review will examine the extent to which inconsistent clinical pathways drive disparities in outcomes; and what steps he plans to take to ensure that adults, young people and children in every Integrated Care Board area receive timely, consistent and clinically robust diagnostic assessment and ongoing support.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
The Department has not made an assessment. We have commissioned an independent review into prevalence and support for mental health conditions, attention deficit hyperactivity disorder (ADHD), and autism. The review will look to understand the similarities and difference between mental health conditions, ADHD, and autism. It will look at prevalence, early intervention and treatment, and the current challenges facing clinical services. This will include exploring the factors that have contributed to the increase in prevalence and inequalities in access and outcomes. It will also examine the extent to which diagnosis, medicalisation, and treatment improve outcomes for individuals. This will include exploring the evidence around clinical practice and the risks and benefits of medicalisation.
The review will appoint an Advisory Working Group which involves a multidisciplinary group of leading academics, clinicians, epidemiological experts, charities, and people with lived experience to directly shape the recommendations and scrutinise the evidence.
The chairs will provide a short report within six months setting out conclusions and recommendations for responding to the rising need, both within the Government and across the health system and wider public services.
As this is an independent review, it is therefore for the Chair and vice-chairs to explore and consider topics and themes relevant to the terms of reference. It would not be appropriate for the Department to comment or influence further on specific topics, findings, and recommendations. The Government will consider any recommendations and respond accordingly.